Research and Markets (http://www.researchandmarkets.com/research/wx8p6b/frontier_pharma) has announced the addition of the "Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation" report to their offering.
The Parkinson's disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes.
This diversity is partially due to the presence of 90 first-in-class products, which account for 37% of the overall pipeline therapies that disclosed their target. In an industry, a market and development landscape that favors first-in-class over non-first-in-class development in many ways, such as through faster approval or greater revenue, has strategic implications for a wide array of market participants, both large and small. Despite their historically high attrition rate, first-in-class therapies that reach the market have the potential to transform and improve the PD treatment landscape.
A brief introduction to PD, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms, coverage of the changing molecular target landscape and particular points of innovation in the pipeline A comprehensive review of the pipeline for first-in-class therapies, analyzed by stage of development, molecule type and molecular target Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets Industry-wide analysis of first-in-class deals compared to non-first-in-class deals An assessment of the licensing and co-development deal landscape for PD therapies and benchmarking of deals comparing first-in-class and non-first-in-class-products
Reasons to Purchase:
Understand the focal shifts in molecular targets in the PD pipeline Understand the distribution of pipeline programs by phase of development, molecule type and molecular target Access a scientific and clinical analysis of first-in-class developmental programs for PD, benchmarked against non-first-in-class targets Assess the valuations of licensed and co-developed PD treatments Access a list of the first-in-class therapies potentially open to deal-making opportunities
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signaling Network, Parkinson's Disease Genetics and Innovation Alignment
7 First-in-Class Target and Pipeline Program Evaluation
8 Deals and Strategic Consolidations
For more information visit http://www.researchandmarkets.com/research/wx8p6b/frontier_pharma.
SOURCE: Research and Markets
Research and Markets Laura Wood, Senior Manager email@example.com For EST Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals, Diagnostics